Summary & Overview
HCPCS Q5134: Injection, natalizumab-sztn (Tyruko), biosimilar, 1 mg
HCPCS Level II code Q5134 designates a 1 mg injection of natalizumab-sztn (Tyruko), a biosimilar monoclonal antibody used as an injectable biologic. As a drug-specific HCPCS Level II code, Q5134 is used to report the product administered to patients receiving outpatient infusion or ambulatory infusion services. This code matters nationally because biosimilar biologics influence drug spending, access to specialty therapies, and payer coverage policies across public and commercial plans.
Key payers addressed in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of how the code is categorized, the clinical context for its use, and typical sites of service. The publication outlines benchmark considerations for drug reporting, summarizes common modifier usage where applicable (Data not available in the input), and flags areas where payer policy and billing practices commonly affect reimbursement and claims processing.
The report provides actionable reference material for billing managers, revenue cycle staff, and policy analysts seeking clarity on code definition, clinical purpose, and administrative handling of a biosimilar injectable therapy in outpatient infusion settings. Data not available in the input is noted where specific payer policies, associated taxonomies, ICD-10 pairings, and related codes would normally appear.
Billing Code Overview
HCPCS Level II code Q5134 represents an injection of natalizumab-sztn (Tyruko), biosimilar, 1 mg. This code describes the pharmaceutical product administered via injection and is used to report the drug itself rather than separate administration services.
Service type: Injectable biologic (monoclonal antibody biosimilar)
Typical site of service: Outpatient infusion clinic or ambulatory infusion center
Clinical & Coding Specifications
Clinical Context
A typical patient is an adult with relapsing-remitting multiple sclerosis (RRMS) receiving maintenance infusion therapy with natalizumab biosimilar Q5134 (natalizumab-sztn, Tyruko) dosed per manufacturer guidance. The clinical workflow begins with outpatient neurology infusion center scheduling for an infusion appointment. Pre-visit steps include verification of diagnosis, review of prior infusion tolerance, screening for progressive multifocal leukoencephalopathy (PML) risk (including John Cunningham virus serology and prior immunosuppressant history), baseline vital signs, and review of pregnancy status for women of childbearing potential.
On the day of service the patient arrives to an infusion suite or hospital outpatient infusion center. A registered nurse performs an intake assessment, documents allergies, obtains baseline vitals, and establishes intravenous access if required (depending on product formulation and institutional protocol). The pharmacy verifies medication preparation and label, including dose calculated from the medication order and expiry. The provider documents informed consent for off-label or biosimilar substitution if required by facility policy. The infusion is administered under nursing supervision with monitoring for infusion-related reactions; medications for acute hypersensitivity are available. Post-infusion observation is typically 30–60 minutes depending on prior tolerance. Billing uses HCPCS Level II code Q5134 for the drug product (per mg unit), with appropriate modifiers appended when clinically relevant and with an infusion administration CPT code billed by the facility or clinician as applicable.
Coding Specifications
| Modifier | Description | When to Use |
|---|